UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.

03/01/2024 03/01/2024

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

07/10/2023 07/10/2023

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

20/09/2023 20/09/2023

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression

Our integrative model aims to bridge the biomedical-psychedelic divide to offer a feasible, flexible, and standardized approach to ketamine for TRD. Our learnings from developing and implementing this psychedelic-inspired model for severe, real-world patients in two academic hospitals may offer valuable insights for the ongoing roll-out of a range of psychedelic therapies.

15/02/2023 15/02/2023

Treating depression with Esketamine

05/11/2022 05/11/2022

Single-dose psilocybin for a treatment-resistant episode of major depression

In ... participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly ... over a period of 3 weeks.

15/10/2022 15/10/2022

COMPASS pathways announces phase 3 pivotal program design for COMP360 in treatment resistant depression

COMPASS’ program will be the first ever Phase 3 program of psilocybin therapy.